

Cutter



REF:WE-306

TO M. Mozen / R. Rousell

DATE 17 June 1983

FROM: W. Ewald
SUBJECT:

RECEIVED

COPIES TO: J. N. Ashworth
B. Cole
P. DeHart
E. Greene

JUN 2 1983

CLINICAL RESEARCH

In our efforts to deal with heat-treated Factor VIII concentrates in the marketplace, where we are competing with our ordinary Koate®, we have been devising various strategies and ideas.

Pete DeHart has come up with an idea that ALT screening might give us something to say about the safety of Koate®. For your information, I am attaching various pieces of correspondence.

Would you please be so kind to evaluate the merits or demerits of an ALT screening program. In particular, answers to the following questions would be most helpful:

1. Would an ALT screening program give us anything to say about possible reduction for AIDS transmission?
2. If we were to start an ALT screening program, how long approximately would it take until we would have finished product available after the decision to do the screening would be made?
3. If any, what claims could be made?
4. What additional expenses might be incurred in an ALT screening program?

Thank you in advance for your assistance.

GRO-C

rmb

Encl.

112 4181

BAYP0004612_0001